Collaborations, combined therapies and machine learning offer promising strategies for boosting early detection, potential cures
Oct. 28, 2016
| By Diane Mapes / Fred Hutch News Service
Combination therapies. collaborations with patients and partner institutions, a friendly competition to better mammography through machine learning — we talked to a handful of breast cancer researchers about what's happening here at Fred Hutch. There's a lot.
Andrea LaCroix and colleagues tie lasofoxifene to 79 percent lowered overall risk of breast cancer in postmenopausal women
Nov. 8, 2010
The osteoporosis drug lasofoxifene statistically reduced the overall risk of breast cancer, as well as estrogen receptor positive invasive breast cancer in postmenopausal women with low bone density, according to a study led by Dr. Andrea LaCroix of the Public Health Sciences Division of the Fred Hutchinson Cancer Research Center.
Li study confirms his earlier finding that associates long-term tamoxifen use with more than four-fold increased risk of aggressive, difficult to treat type of contralateral breast cancer
Aug. 26, 2009
| By Kristen Woodward
Findings by Dr. Christopher Li, and colleagues at the Fred Hutchinson Cancer Research Center indicate that while long-term tamoxifen use among breast cancer survivors decreases their risk of developing the most common, less aggressive type of second breast cancer, such use is associated with a more than four-fold increased risk of a more aggressive, difficult-to-treat type of cancer in the breast opposite, or contralateral, to the initial tumor.